Share Price and Basic Stock Data
Last Updated: December 16, 2025, 10:58 pm
| PEG Ratio | 0.61 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Crestchem Ltd operates within the organic chemicals sector, a niche that has shown remarkable growth potential. As of March 2025, the company reported sales of ₹24.98 Cr, a notable increase from ₹16.66 Cr the previous fiscal year. This upward trajectory in revenue aligns with a broader industry trend where demand for specialty chemicals continues to rise, driven by various sectors including pharmaceuticals and agriculture. The quarterly sales data also reflects this growth; for instance, in Q4 FY 2025, Crestchem recorded sales of ₹7.23 Cr, compared to ₹5.63 Cr in the previous quarter, indicating a strong seasonal performance. While the company’s operating profit margin (OPM) stood at a modest 13.29%, it is essential to recognize that the firm has successfully transitioned from a historical phase of fluctuating revenues and losses to a more stable growth pattern. Nonetheless, the volatility in quarterly sales, particularly the dip to ₹2.87 Cr in Q4 FY 2023, raises questions about the sustainability of this growth momentum.
Profitability and Efficiency Metrics
The profitability metrics for Crestchem reveal a company that is not only recovering but thriving in recent years. The net profit for FY 2025 reached ₹2.73 Cr, a significant leap from ₹0.69 Cr in FY 2023, showcasing a robust improvement in operational efficiency. The return on equity (ROE) is particularly impressive at 44.1%, indicating that the company is generating substantial returns for its shareholders. Coupled with a return on capital employed (ROCE) of 59.9%, Crestchem seems to be utilizing its capital effectively to generate profits. However, the operating profit margin of 13.29% suggests that while the company is profitable, it operates within a competitive environment where margins can be thin. The cash conversion cycle stands at 37.41 days, which is relatively efficient and points to effective management of receivables and inventory, although it also indicates potential challenges in liquidity during periods of slower sales.
Balance Sheet Strength and Financial Ratios
Crestchem’s balance sheet reflects a strong financial position, especially highlighted by the absence of any borrowings, standing at ₹0.00 Cr. This zero-debt status enhances the company’s financial flexibility, allowing it to pursue growth opportunities without the burden of interest payments. The equity capital has remained stable at ₹3.00 Cr, while reserves have notably increased to ₹4.48 Cr as of FY 2025, a positive sign of retained earnings being reinvested back into the business. The price-to-book value ratio (P/BV) of 8.29x does appear elevated, suggesting that the stock may be priced on the higher side relative to its book value, which could deter some value-focused investors. The interest coverage ratio is exceptionally high at 271.82x, reflecting the company’s strong capacity to meet its interest obligations, although this is somewhat moot given there are no borrowings. Overall, the balance sheet appears robust, but the high valuation metrics could be a point of concern for potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Crestchem Ltd reveals an interesting mix of ownership, with promoters holding 29.69% of the company as of March 2025. The public holds a significant 70.19%, indicating a broad base of retail investor participation, which can be a positive signal for market confidence. However, the low institutional investor participation, with domestic institutional investors (DIIs) at a mere 0.13%, raises questions about the stock’s attractiveness to larger, more stable investment funds. The growing number of shareholders, which rose to 12,851, reflects increasing interest in the company, even as the promoter holding has slightly declined from previous periods. This could indicate a dilution of control, which might concern some investors. Nevertheless, the stability in promoter holding coupled with a high public stake underscores a level of confidence in the company’s future prospects, even as the institutional presence remains notably sparse.
Outlook, Risks, and Final Insight
Looking ahead, Crestchem’s growth story is promising, but not without its risks. The company’s ability to maintain its revenue growth amidst fluctuating quarterly performance could be a significant challenge. Additionally, the thin operating margins suggest that any increase in costs could impact profitability sharply. The lack of institutional backing might also limit the stock’s liquidity and could contribute to volatility in share price. On the flip side, the absence of debt provides a cushion against economic downturns, and the impressive ROE and ROCE figures indicate effective management and profitability. Investors might consider keeping a close watch on quarterly results and industry trends, especially given the potential for competitive pressures in the organic chemicals market. Overall, Crestchem presents an intriguing investment case; its strong fundamentals are tempered by inherent risks that require careful consideration by investors seeking exposure to this niche sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 98.6 Cr. | 276 | 456/255 | 229 | 392 | 0.03 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,731 Cr. | 9,752 | 14,250/8,150 | 56.0 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 35.8 Cr. | 119 | 329/109 | 17.7 | 26.9 | 0.84 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 307 Cr. | 384 | 435/163 | 17.0 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,633.33 Cr | 1,548.66 | 65.14 | 334.84 | 0.40% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.80 | 3.89 | 5.17 | 2.87 | 3.78 | 4.49 | 7.36 | 5.63 | 5.25 | 7.80 | 4.80 | 7.23 | 5.03 |
| Expenses | 4.63 | 3.74 | 4.71 | 2.83 | 3.51 | 4.08 | 6.13 | 4.78 | 4.49 | 6.53 | 4.15 | 6.63 | 4.67 |
| Operating Profit | 0.17 | 0.15 | 0.46 | 0.04 | 0.27 | 0.41 | 1.23 | 0.85 | 0.76 | 1.27 | 0.65 | 0.60 | 0.36 |
| OPM % | 3.54% | 3.86% | 8.90% | 1.39% | 7.14% | 9.13% | 16.71% | 15.10% | 14.48% | 16.28% | 13.54% | 8.30% | 7.16% |
| Other Income | 0.03 | 0.03 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.09 | 0.08 | 0.12 | 0.09 | 0.14 | 0.13 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| Profit before tax | 0.20 | 0.17 | 0.48 | 0.08 | 0.32 | 0.46 | 1.28 | 0.93 | 0.83 | 1.38 | 0.73 | 0.72 | 0.47 |
| Tax % | 25.00% | 23.53% | 27.08% | 12.50% | 25.00% | 26.09% | 28.91% | 27.96% | 27.71% | 28.26% | 27.40% | 15.28% | 25.53% |
| Net Profit | 0.14 | 0.12 | 0.36 | 0.07 | 0.24 | 0.34 | 0.91 | 0.66 | 0.60 | 1.00 | 0.52 | 0.61 | 0.35 |
| EPS in Rs | 0.47 | 0.40 | 1.20 | 0.23 | 0.80 | 1.13 | 3.03 | 2.20 | 2.00 | 3.33 | 1.73 | 2.03 | 1.17 |
Last Updated: August 19, 2025, 8:35 pm
Below is a detailed analysis of the quarterly data for Crestchem Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.03 Cr.. The value appears to be declining and may need further review. It has decreased from 7.23 Cr. (Mar 2025) to 5.03 Cr., marking a decrease of 2.20 Cr..
- For Expenses, as of Jun 2025, the value is 4.67 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.63 Cr. (Mar 2025) to 4.67 Cr., marking a decrease of 1.96 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.36 Cr.. The value appears to be declining and may need further review. It has decreased from 0.60 Cr. (Mar 2025) to 0.36 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Jun 2025, the value is 7.16%. The value appears to be declining and may need further review. It has decreased from 8.30% (Mar 2025) to 7.16%, marking a decrease of 1.14%.
- For Other Income, as of Jun 2025, the value is 0.13 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Mar 2025) to 0.13 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.47 Cr., marking a decrease of 0.25 Cr..
- For Tax %, as of Jun 2025, the value is 25.53%. The value appears to be increasing, which may not be favorable. It has increased from 15.28% (Mar 2025) to 25.53%, marking an increase of 10.25%.
- For Net Profit, as of Jun 2025, the value is 0.35 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Mar 2025) to 0.35 Cr., marking a decrease of 0.26 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.17. The value appears to be declining and may need further review. It has decreased from 2.03 (Mar 2025) to 1.17, marking a decrease of 0.86.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.42 | 0.09 | 0.13 | 0.14 | 0.05 | 0.10 | 6.15 | 7.62 | 7.90 | 16.66 | 21.18 | 24.98 | 24.25 |
| Expenses | 0.36 | 0.23 | 0.18 | 0.34 | 0.29 | 0.26 | 5.59 | 6.95 | 7.15 | 15.84 | 18.40 | 21.66 | 22.03 |
| Operating Profit | 0.06 | -0.14 | -0.05 | -0.20 | -0.24 | -0.16 | 0.56 | 0.67 | 0.75 | 0.82 | 2.78 | 3.32 | 2.22 |
| OPM % | 14.29% | -155.56% | -38.46% | -142.86% | -480.00% | -160.00% | 9.11% | 8.79% | 9.49% | 4.92% | 13.13% | 13.29% | 9.15% |
| Other Income | 0.03 | 0.89 | 0.19 | 0.08 | 0.03 | 0.02 | 0.03 | 0.05 | 0.08 | 0.15 | 0.26 | 0.44 | 0.51 |
| Interest | 0.03 | 0.02 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.05 | 0.00 |
| Depreciation | 0.08 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 | 0.02 | 0.05 | 0.05 | 0.07 |
| Profit before tax | -0.02 | 0.68 | 0.12 | -0.16 | -0.22 | -0.16 | 0.57 | 0.68 | 0.78 | 0.94 | 2.98 | 3.66 | 2.66 |
| Tax % | 0.00% | 10.29% | 25.00% | 0.00% | -13.64% | 0.00% | 22.81% | 14.71% | 26.92% | 26.60% | 27.85% | 25.41% | |
| Net Profit | -0.03 | 0.61 | 0.09 | -0.16 | -0.19 | -0.17 | 0.44 | 0.57 | 0.57 | 0.69 | 2.15 | 2.73 | 2.02 |
| EPS in Rs | -0.10 | 2.03 | 0.30 | -0.53 | -0.63 | -0.57 | 1.47 | 1.90 | 1.90 | 2.30 | 7.17 | 9.10 | 6.73 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.98% | 10.99% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2133.33% | -85.25% | -277.78% | -18.75% | 10.53% | 358.82% | 29.55% | 0.00% | 21.05% | 211.59% | 26.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2218.58% | -192.53% | 259.03% | 29.28% | 348.30% | -329.28% | -29.55% | 21.05% | 190.54% | -184.62% |
Crestchem Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 76% |
| 5 Years: | 32% |
| 3 Years: | 47% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 44% |
| 3 Years: | 69% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 43% |
| 3 Years: | 42% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 44% |
| 3 Years: | 45% |
| Last Year: | 44% |
Last Updated: September 5, 2025, 3:06 pm
Balance Sheet
Last Updated: December 10, 2025, 4:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves | -2.59 | -2.09 | -2.00 | -2.16 | -2.36 | -2.53 | -2.08 | -1.51 | -0.94 | -0.25 | 1.90 | 4.48 | 5.07 |
| Borrowings | 0.40 | 0.37 | 0.35 | 0.60 | 0.14 | 0.28 | 0.02 | 0.63 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.49 | 0.22 | 0.05 | 0.05 | 0.04 | 0.14 | 1.35 | 0.87 | 0.96 | 2.04 | 2.24 | 3.07 | 5.48 |
| Total Liabilities | 1.30 | 1.50 | 1.40 | 1.49 | 0.82 | 0.89 | 2.29 | 2.99 | 3.29 | 4.79 | 7.14 | 10.55 | 13.55 |
| Fixed Assets | 0.46 | 0.04 | 0.04 | 0.04 | 0.11 | 0.12 | 0.10 | 0.14 | 0.11 | 0.10 | 0.17 | 0.26 | 0.23 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.84 | 1.46 | 1.36 | 1.45 | 0.71 | 0.77 | 2.19 | 2.85 | 3.18 | 4.69 | 6.97 | 10.29 | 13.32 |
| Total Assets | 1.30 | 1.50 | 1.40 | 1.49 | 0.82 | 0.89 | 2.29 | 2.99 | 3.29 | 4.79 | 7.14 | 10.55 | 13.55 |
Below is a detailed analysis of the balance sheet data for Crestchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 4.48 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 0.59 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.48 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.07 Cr. (Mar 2025) to 5.48 Cr., marking an increase of 2.41 Cr..
- For Total Liabilities, as of Sep 2025, the value is 13.55 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.55 Cr. (Mar 2025) to 13.55 Cr., marking an increase of 3.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.23 Cr., marking a decrease of 0.03 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13.32 Cr.. The value appears strong and on an upward trend. It has increased from 10.29 Cr. (Mar 2025) to 13.32 Cr., marking an increase of 3.03 Cr..
- For Total Assets, as of Sep 2025, the value is 13.55 Cr.. The value appears strong and on an upward trend. It has increased from 10.55 Cr. (Mar 2025) to 13.55 Cr., marking an increase of 3.00 Cr..
Notably, the Reserves (5.07 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.34 | -0.51 | -0.40 | -0.80 | -0.38 | -0.44 | 0.54 | 0.04 | 0.48 | 0.82 | 2.78 | 3.32 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 356.31 | 0.00 | 336.92 | 469.29 | 730.00 | 292.00 | 71.81 | 67.54 | 41.58 | 0.44 | 26.37 | 37.41 |
| Inventory Days | 0.00 | 60.83 | 0.00 | 73.00 | 0.00 | 182.50 | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days Payable | 60.83 | 73.00 | 365.00 | 91.06 | ||||||||
| Cash Conversion Cycle | 356.31 | 0.00 | 336.92 | 469.29 | 730.00 | 109.50 | -18.50 | 67.54 | 41.58 | 0.44 | 26.37 | 37.41 |
| Working Capital Days | -234.64 | -1,987.22 | -645.77 | -1,016.79 | 438.00 | -292.00 | 3.56 | 12.93 | -2.77 | -36.81 | -1.21 | 8.47 |
| ROCE % | 1.30% | -13.40% | 10.65% | -8.60% | -18.92% | -19.61% | 67.46% | 45.75% | 35.96% | 37.40% | 78.17% | 59.94% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.09 | 7.15 | 2.31 | 1.89 | 19.91 |
| Diluted EPS (Rs.) | 9.09 | 7.15 | 2.31 | 1.89 | 19.91 |
| Cash EPS (Rs.) | 9.26 | 7.31 | 2.39 | 1.98 | 1.99 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.92 | 16.33 | 9.18 | 6.87 | 4.97 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.92 | 16.33 | 9.18 | 6.87 | 4.97 |
| Dividend / Share (Rs.) | 1.00 | 0.50 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 83.59 | 70.85 | 55.76 | 26.49 | 25.47 |
| PBDIT / Share (Rs.) | 12.41 | 10.11 | 3.23 | 2.74 | 2.38 |
| PBIT / Share (Rs.) | 12.23 | 9.96 | 3.16 | 2.66 | 2.30 |
| PBT / Share (Rs.) | 12.19 | 9.93 | 3.13 | 2.60 | 2.24 |
| Net Profit / Share (Rs.) | 9.09 | 7.15 | 2.31 | 1.89 | 1.91 |
| PBDIT Margin (%) | 14.84 | 14.27 | 5.80 | 10.35 | 9.33 |
| PBIT Margin (%) | 14.63 | 14.05 | 5.66 | 10.02 | 9.02 |
| PBT Margin (%) | 14.58 | 14.01 | 5.60 | 9.82 | 8.81 |
| Net Profit Margin (%) | 10.87 | 10.09 | 4.14 | 7.13 | 7.51 |
| Return on Networth / Equity (%) | 36.46 | 43.80 | 25.18 | 27.53 | 38.46 |
| Return on Capital Employeed (%) | 48.63 | 60.53 | 34.26 | 38.57 | 44.70 |
| Return On Assets (%) | 25.85 | 30.04 | 14.48 | 17.22 | 19.14 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.12 | 0.42 |
| Asset Turnover Ratio (%) | 2.84 | 3.56 | 4.14 | 2.53 | 2.89 |
| Current Ratio (X) | 1.44 | 1.04 | 0.60 | 0.95 | 1.85 |
| Quick Ratio (X) | 1.44 | 1.04 | 0.60 | 0.95 | 1.85 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 11553.39 | 2181.02 | 1235.35 |
| Interest Coverage Ratio (X) | 271.82 | 430.21 | 98.75 | 52.20 | 44.41 |
| Interest Coverage Ratio (Post Tax) (X) | 200.07 | 305.40 | 71.56 | 36.98 | 36.75 |
| Enterprise Value (Cr.) | 61.25 | 34.07 | 35.86 | 12.56 | 7.51 |
| EV / Net Operating Revenue (X) | 2.44 | 1.60 | 2.14 | 1.58 | 0.98 |
| EV / EBITDA (X) | 16.45 | 11.23 | 36.95 | 15.26 | 10.53 |
| MarketCap / Net Operating Revenue (X) | 2.47 | 1.61 | 2.20 | 1.55 | 1.03 |
| Price / BV (X) | 8.29 | 6.98 | 13.34 | 5.97 | 5.27 |
| Price / Net Operating Revenue (X) | 2.47 | 1.61 | 2.20 | 1.55 | 1.03 |
| EarningsYield | 0.04 | 0.06 | 0.01 | 0.04 | 0.07 |
After reviewing the key financial ratios for Crestchem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.26. This value is within the healthy range. It has increased from 7.31 (Mar 24) to 9.26, marking an increase of 1.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.92. It has increased from 16.33 (Mar 24) to 24.92, marking an increase of 8.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.92. It has increased from 16.33 (Mar 24) to 24.92, marking an increase of 8.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.00. This value is within the healthy range. It has increased from 0.50 (Mar 24) to 1.00, marking an increase of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 83.59. It has increased from 70.85 (Mar 24) to 83.59, marking an increase of 12.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 12.41. This value is within the healthy range. It has increased from 10.11 (Mar 24) to 12.41, marking an increase of 2.30.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.23. This value is within the healthy range. It has increased from 9.96 (Mar 24) to 12.23, marking an increase of 2.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 9.93 (Mar 24) to 12.19, marking an increase of 2.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 9.09, marking an increase of 1.94.
- For PBDIT Margin (%), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 14.27 (Mar 24) to 14.84, marking an increase of 0.57.
- For PBIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has increased from 14.05 (Mar 24) to 14.63, marking an increase of 0.58.
- For PBT Margin (%), as of Mar 25, the value is 14.58. This value is within the healthy range. It has increased from 14.01 (Mar 24) to 14.58, marking an increase of 0.57.
- For Net Profit Margin (%), as of Mar 25, the value is 10.87. This value exceeds the healthy maximum of 10. It has increased from 10.09 (Mar 24) to 10.87, marking an increase of 0.78.
- For Return on Networth / Equity (%), as of Mar 25, the value is 36.46. This value is within the healthy range. It has decreased from 43.80 (Mar 24) to 36.46, marking a decrease of 7.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 48.63. This value is within the healthy range. It has decreased from 60.53 (Mar 24) to 48.63, marking a decrease of 11.90.
- For Return On Assets (%), as of Mar 25, the value is 25.85. This value is within the healthy range. It has decreased from 30.04 (Mar 24) to 25.85, marking a decrease of 4.19.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.84. It has decreased from 3.56 (Mar 24) to 2.84, marking a decrease of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 1.5. It has increased from 1.04 (Mar 24) to 1.44, marking an increase of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.44, marking an increase of 0.40.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 271.82. This value is within the healthy range. It has decreased from 430.21 (Mar 24) to 271.82, marking a decrease of 158.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 200.07. This value is within the healthy range. It has decreased from 305.40 (Mar 24) to 200.07, marking a decrease of 105.33.
- For Enterprise Value (Cr.), as of Mar 25, the value is 61.25. It has increased from 34.07 (Mar 24) to 61.25, marking an increase of 27.18.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.44, marking an increase of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is 16.45. This value exceeds the healthy maximum of 15. It has increased from 11.23 (Mar 24) to 16.45, marking an increase of 5.22.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.47, marking an increase of 0.86.
- For Price / BV (X), as of Mar 25, the value is 8.29. This value exceeds the healthy maximum of 3. It has increased from 6.98 (Mar 24) to 8.29, marking an increase of 1.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.47, marking an increase of 0.86.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.04, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Crestchem Ltd:
- Net Profit Margin: 10.87%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 48.63% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 36.46% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 200.07
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.44
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.7 (Industry average Stock P/E: 65.14)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.87%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Sr. No.550/1, Sub Plot Number 12, Mehsana Dist. Gujarat 382715 | info@crestchemlimited.in http://www.crestchemlimited.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dipak Narendraprasad Patel | Promoter, Chairman & Managing Director |
| Mr. Nitinkumar Shantilal Shah | Non Exe. & Ind. Director |
| Mrs. Rinkal Maulik Jasani | Non Exe. Women Independent Director |
| Mrs. Priyankaben M Patel | Ind. Non-Executive Director |
| Mr. Jignesh A Shah | Ind. Non-Executive Director |
| Mr. Nirmit Dipak Patel | Executive Director |
FAQ
What is the intrinsic value of Crestchem Ltd?
Crestchem Ltd's intrinsic value (as of 17 December 2025) is 169.39 which is 42.34% higher the current market price of 119.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 35.8 Cr. market cap, FY2025-2026 high/low of 329/109, reserves of ₹5.07 Cr, and liabilities of 13.55 Cr.
What is the Market Cap of Crestchem Ltd?
The Market Cap of Crestchem Ltd is 35.8 Cr..
What is the current Stock Price of Crestchem Ltd as on 17 December 2025?
The current stock price of Crestchem Ltd as on 17 December 2025 is 119.
What is the High / Low of Crestchem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Crestchem Ltd stocks is 329/109.
What is the Stock P/E of Crestchem Ltd?
The Stock P/E of Crestchem Ltd is 17.7.
What is the Book Value of Crestchem Ltd?
The Book Value of Crestchem Ltd is 26.9.
What is the Dividend Yield of Crestchem Ltd?
The Dividend Yield of Crestchem Ltd is 0.84 %.
What is the ROCE of Crestchem Ltd?
The ROCE of Crestchem Ltd is 59.9 %.
What is the ROE of Crestchem Ltd?
The ROE of Crestchem Ltd is 44.1 %.
What is the Face Value of Crestchem Ltd?
The Face Value of Crestchem Ltd is 10.0.